Home » Stocks » MOLN

Molecular Partners AG (MOLN)

Molecular Partners will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) 10.57M
Net Income (ttm) -70.99M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

Molecular Partners AG has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

While the focus in Switzerland, and elsewhere, has been primarily on vaccines in the past few months, a new medication may also offer hope in the fight against Covid-19. This is what we know about this ...

3 weeks ago - The Local

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients.

1 month ago - BioSpace

About MOLN

Molecular Partners is a clinical stage biopharmaceutical company applying our pioneering DARPinĀ® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
Dr. Patrick Amstutz
Employees
145
Stock Exchange
NASDAQ
Ticker Symbol
MOLN
Full Company Profile

Financial Performance

In 2020, MOLN's revenue was 9.34 million, a decrease of -54.16% compared to the previous year's 20.38 million. Losses were -62.76 million, 73.0% more than in 2019.

Financial numbers in millions CHF.
Financial Statements